

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CStone Pharmaceuticals**  
**基石藥業**

*(Incorporated in the Cayman Islands with limited liability)*  
**(Stock Code: 2616)**

**DATE OF BOARD MEETING**

The board (the “**Board**”) of directors (the “**Directors**”) of CStone Pharmaceuticals (the “**Company**”) hereby announces that a meeting of the Board will be held on Thursday, August 25, 2022, for the purposes of, among other matters, considering and approving the interim results of the Company and its subsidiaries for the six months ended June 30, 2022 and its publication, and considering the recommendation on the payment of an interim dividend, if any.

By order of the Board  
**CStone Pharmaceuticals**  
**Dr. Wei Li**  
*Chairman*

Suzhou, the People’s Republic of China, August 15, 2022

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Wei Li as Chairman and non-executive Director, Dr. Frank Ningjun Jiang as executive Director, Mr. Kenneth Walton Hitchner III, Mr. Yanling Cao, Mr. Xianghong Lin and Mr. Edward Hu as non-executive Directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive Directors.*